当前位置: 首页 > 详情页

Levodopa Effect on Basal Ganglia Motor Circuit in Parkinson's Disease

| 导出 | |

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Department of Neurobiology, Key Laboratory on Neurodegenerative Disorders of Ministry of Education, Beijing Institute of Geriatrics, Xuanwu Hospital, Capital Medical University, Beijing, China [2]Beijing Key Laboratory on Parkinson’s Disease, Parkinson Disease Center of Beijing Institute for Brain Disorders, Beijing, China
出处:
ISSN:

关键词: Basal ganglia motor circuit Bradykinesia Connectivity Levodopa Parkinson's disease

摘要:
Aims: To investigate the effects of levodopa on the basal ganglia motor circuit (BGMC) in Parkinson's disease (PD). Methods: Thirty PD patients with asymmetrical bradykinesia and 30 control subjects were scanned using resting-state functional MRI. Functional connectivity of the BGMC was measured and compared before and after levodopa administration in patients with PD. The correlation between improvements in bradykinesia and changes in BGMC connectivity was examined. Results: In the PD-off state (before medication), the posterior putamen and internal globus pallidus (GPi) had decreased connectivity while the subthalamic nucleus (STN) had enhanced connectivity within the BGMC relative to control subjects. Levodopa administration increased the connectivity of posterior putamen-and GPi-related networks but decreased the connectivity of STN-related networks. Improvements in bradykinesia were correlated with enhanced connectivity of the posterior putamen- cortical motor pathway and with decreased connectivity of the STN-thalamo-cortical motor pathway. Conclusion: In PD patients with asymmetrical bradykinesia, levodopa can partially normalize the connectivity of the BGMC with a larger effect on the more severely affected side. Moreover, the beneficial effect of levodopa on bradykinesia is associated with normalization of the striato-thalamo-cortical motor and STN-cortical motor pathways. Our findings inform the neural mechanism of levodopa treatment in PD.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 2 区 医学
小类 | 2 区 药学 3 区 神经科学
最新[2023]版:
大类 | 1 区 医学
小类 | 2 区 神经科学 2 区 药学
JCR分区:
出版当年[2015]版:
Q1 PHARMACOLOGY & PHARMACY Q2 NEUROSCIENCES
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q1 NEUROSCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者机构: [1]Department of Neurobiology, Key Laboratory on Neurodegenerative Disorders of Ministry of Education, Beijing Institute of Geriatrics, Xuanwu Hospital, Capital Medical University, Beijing, China [2]Beijing Key Laboratory on Parkinson’s Disease, Parkinson Disease Center of Beijing Institute for Brain Disorders, Beijing, China
通讯作者:
通讯机构: [*1]Department of Neurobiology, Key Laboratory on Neurodegenerative Disorders of Ministry of Education, Beijing Institute of Geriatrics, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院